{"id":"chop-daclizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The CHOP component is a standard cytotoxic chemotherapy regimen that directly kills rapidly dividing cancer cells. Daclizumab targets CD25 (the alpha chain of the IL-2 receptor) on regulatory T cells, reducing immunosuppression and allowing enhanced anti-tumor immunity. This combination approach aims to improve outcomes in T-cell lymphomas by combining direct cytotoxic effects with immune modulation.","oneSentence":"CHOP-daclizumab is a chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) combined with daclizumab, an anti-CD25 monoclonal antibody that depletes regulatory T cells to enhance immune response against lymphoid malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:20.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"T-cell lymphomas (cutaneous and systemic)"}]},"trialDetails":[{"nctId":"NCT01418430","phase":"PHASE4","title":"Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"","conditions":"HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CHOP-Zenapax"],"phase":"marketed","status":"active","brandName":"CHOP-daclizumab","genericName":"CHOP-daclizumab","companyName":"King's College Hospital NHS Trust","companyId":"king-s-college-hospital-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP-daclizumab is a combination therapy that includes the drug daclizumab, which is an interleukin-2 receptor inhibitor. It is being studied as a treatment for HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}